NJ-OPEX
13.6.2024 15:06:34 CEST | Business Wire | Press release
OPEX® Corporation, a global leader in Next Generation Automation for warehouse, document and mail automation, has been selected by the SupplyTech Breakthrough Awards program as the winner of the 2024 Sortation System Innovation of the Year Award for OPEX Sure Sort® X with OPEX Xtract™.
This annual awards program is conducted by SupplyTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout technology companies, products and services in the supply chain technology and logistics industry around the globe.
OPEX Sure Sort X with OPEX Xtract, introduced in March 2024, represents the next generation of high-speed automated sortation and order retrieval solutions. It is a fully adaptable, turnkey offering designed to automate numerous manual tasks with a simple, one-touch approach.
“We’re honored to receive this prestigious award from SupplyTech Breakthrough,” said Alex Stevens, President of Warehouse Automation at OPEX. “Our goal in developing Sure Sort X with Xtract was to meet the evolving demands of the marketplace by delivering one integrated solution that sorts, retrieves, and dispenses items into a shipping container, without the intervention of a human operator. We’re incredibly proud that our teams’ unique and powerful solution has been recognized as the 2024 Sortation System Innovation of the Year.”
This year’s SupplyTech Breakthrough Awards program attracted thousands of nominations from over 15 different countries around the world.
“OPEX’s solutions significantly increase overall efficiency and directly address ongoing labor challenges. With the difficulty of attracting and retaining staff, automated sortation systems help to address this challenge while also improving workflows, from product arrival to sorting for picking, packaging, and shipping,” said Bryan Vaughn, Managing Director of SupplyTech Breakthrough Awards. “With OPEX Sure Sort X with Xtract, our Sortation System Innovation of the Year, the future of warehouse automation has arrived.”
OPEX Sure Sort X is a versatile and robust industrial sorting solution that can handle nearly 100% of customer-sortable items weighing up to 20 pounds (9 kilograms), and sort them into a configurable array of mixed bin sizes and types, all while maintaining a consistent throughput of up to 2,100 items per hour.
When Sure Sort X is paired with Xtract, an automated order retrieval system, the task of retrieving totes and transferring their contents into shipping containers is fully automated as well, eliminating the need to manually sort and transfer boxes downstream. Xtract can be added to any Sure Sort X system by introducing retrieval iBOTs to work in conjunction with the traditional sortation iBOTs found in Sure Sort X.
OPEX Sure Sort X with Xtract can accommodate multiple market vertical workflows and exponentially reduces the need for human interface.
About OPEX
OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future.
About SupplyTech Breakthrough
Part of the Tech Breakthrough organization, a leading global provider of market intelligence and recognition platforms for technology innovation and leadership, the SupplyTech Breakthrough Awards program is devoted to honoring innovation and market disruption in supply chain and logistics technologies, services, companies and products around the world. The annual SupplyTech Breakthrough Awards provide public recognition for the achievements of SupplyTech companies and products in categories including Inventory Management, Supply Chain Visibility, Transportation Management, Material Handling, IoT and Robotics, and more. For more information, visit SupplyTechBreakthrough.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613810864/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom